Invited Commentary on Preventive Anti-Migraine Therapy (PAMT)
- 214 Downloads
Migraine is a chronic paroxysmal neurological disorder characterized by multiphase attacks of head pain and a myriad of neurological symptoms. Chronic migraine causes a great personal and societal burden. Many patients are poorly responsive to, or non-compliant with, conventional migraine preventive therapies. For this reason, physicians are constantly looking for effective migraine prevention strategies. The recent introduction of an innovative pharmacological class useful for migraine prevention, namely monoclonal antibodies towards calcitonin gene-related peptide or its receptors, opens a new, immense therapeutic scenario. In this commentary, the development and efficacy of this novel class of preventive anti-migraine therapy have been discussed and compared with the conventional therapies of migraine prevention.
KeywordsMigraine CGRP monoclonal antibody Migraine prevention CGRP receptor Fremanezumab Erenumab Galcanezumab New migraine treatments Migraine prophylaxis
Compliance with Ethical Standards
Conflict of Interest
Stephen D. Silberstein reports personal fees from Alder Biopharmaceuticals, Allergan, Inc., Amgen, Avanir Pharmaceuticals, Inc., Curelator, Inc., Dr. Reddy’s Laboratories, eNeura Inc., electroCore Medical, LLC, Lilly USA, LLC, Supernus Pharmaceuticals, Inc., Teva Pharmaceuticals, Theranica, Trigemina, Inc., Medscape, LLC, Abide Therapeutics, Biohaven Pharmaceuticals, Cefaly, Egalet, and GlaxoSmithKline, outside the submitted work. Sameer Jain reports no potential conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
- 1.Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of Disease study 2016. Lancet. 2017;390(10100):1211–59.CrossRefGoogle Scholar
- 14.Silberstein S, McAllister P, Berman G, et al. Eptinezumab reduced migraine frequency, duration, and pain intensity through week 24: results from the phase 3 PROMISE-1 trial. Neurology. 2018;90(15):P4.091.Google Scholar
- 15.Lipton R, Saper J, Ashina M. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine: results of the PROMISE-2 (prevention of migraine via intravenous eptinezumab safety and efficacy–2) trial InPlenary Presentation. Am Acad Neurol Conf 2018. 2018.Google Scholar